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Part 1 of a 4-Part Series on Statistics for Clinical TrialsStuart J. Pocock, PHD,* John J.V. McMurray, MD,y Tim J. Collier, MSC*ABSTRACTFro
yIn
tha
MaThis paper is a practical guide to the essentials of statistical analysis and reporting of randomized clinical trials (RCTs). It is
the ﬁrst in a series of 4 educational papers on statistical issues for RCTs, which will also include statistical controversies in
RCT reporting and interpretation, the fundamentals of design for RCTs, and statistical challenges in the design and
monitoring of RCTs. Here, we concentrate on displaying results in tables and ﬁgures, estimating treatment effects,
expressing uncertainty using conﬁdence intervals, and using p values wisely to assess the strength of evidence for a
treatment difference. The various methods and their interpretation are illustrated by recent, topical cardiology trial
results. (J Am Coll Cardiol 2015;66:2536–49) © 2015 by the American College of Cardiology Foundation.S tatistical methods are an essential part ofvirtually all published medical research. Yet, asound understanding of statistical principles
is often lacking amongst researchers and journal
readers, and cardiologists are no exception to this
limitation. In this series of 4 papers in consecutive is-
sues of the Journal, our aim is to illuminate readers
on statistical matters, our focus being on the
design and reporting of randomized controlled trials
(RCTs).
After these ﬁrst 2 papers on statistical analysis and
reporting of clinical trials, 2 subsequent papers will
focus on statistical design of randomized trials and
also data monitoring. The principles are brought to
life by real topical examples, and besides laying
out the fundamentals, we also tackle some common
misperceptions and some ongoing controversies
that affect the quality of research and its valid
interpretation.
Constructive critical appraisal is an art continually
exercised by journal editors, reviewers, and readers,
and is also an integral part of good statistical sciencem the *Department of Medical Statistics, London School of Hygiene & T
stitute of Cardiovascular and Medical Sciences, University of Glasgow, Gl
t they have no relationships relevant to the contents of this paper to dis
nuscript received September 8, 2015; revised manuscript received Octobethat we hope to encourage via our choice of examples.
Throughout this series, we concentrate on concepts
rather than providing formulae or calculation tech-
niques, therefore ensuring that readers without a
mathematical or technical background can grasp the
essential messages we wish to convey.
THE ESSENTIALS OF STATISTICAL ANALYSIS
The 4 main steps in data analysis are:
1. Displaying results in tables and ﬁgures
2. Quantifying any associations (e.g., estimates of
treatment differences in patient outcomes)
3. Expressing the uncertainty in those associations by
use of conﬁdence intervals (CIs)
4. Assessing the strength of evidence that the asso-
ciation is “real” (i.e., more than could be expected
by chance) by using p values (statistical tests of
signiﬁcance)
The next few sections take us through these
essentials, illustrated by examples from randomizedropical Medicine, London, United Kingdom; and the
asgow, United Kingdom. The authors have reported
close.
r 12, 2015, accepted October 18, 2015.
AB BR E V I A T I O N S
AND ACRONYM S
ANCOVA = analysis of
covariance
CABG = coronary artery bypass
grafting
CI = conﬁdence interval
PCI = percutaneous coronary
intervention
RCT = randomized clinical trial
SBP = systolic blood pressure
SD = standard deviation
SE = standard error
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2537trials. The same principles broadly apply to observa-
tional studies, with 1major proviso: in nonrandomized
studies, one cannot readily infer that any association
not due to chance indicates a causal relationship.
Also, next week we discuss some of the more
challenging issues when reporting clinical trials.
DISPLAYING RESULTS IN
TABLES AND FIGURES
TABLE OF BASELINE DATA. The ﬁrst table in any
clinical trial report shows patients’ baseline charac-
teristics by treatment group. Which characteristics to
present will vary by trial, but will almost always
include key demographic variables, related medical
history, and other variables that might be strongly
related to the trial endpoints. See Table 1 as an
example from the PARADIGM-HF trial (Prospective
Comparison of Angiotensin Receptor–Neprilysin In-
hibitor with Angiotensin-Converting–Enzyme Inhibi-
tor to Determine Impact on Global Mortality and
Morbidity in Heart Failure) (1). Note that categorical
variables are shown as number (%) by group. For
quantitative variables, there are 2 common options:
means (and SDs) or median (and interquartile range).
For variables with a skew distribution, the latter is
often preferable, geometric means being another op-
tion. In addition, some such variables may be formed
into categories, for example, age groups or speciﬁc
(abnormal) cut-offs for biochemical variables. This
(and indeed any other table) should include the total
number of patients per group at the top. To limit the
size of Table 1, a third column showing results for all
groups combined may be unnecessary. Also, for some
binary variables (e.g., sex or disease history) only 1
category (e.g., male or diabetic) need be shown. Un-
necessary precision in reporting means or percent-
ages should be avoided, with 1 decimal place usually
being sufﬁcient. The use of p values in baseline tables
should also be avoided, because in the setting of a
well-conducted RCT, any differences at baseline must
have arisen by chance.
TABLE OF MAIN OUTCOME EVENTS. The key table for
any clinical trial displays the main outcomes by treat-
ment group. For trials concentrating on clinical events
during follow-up, the numbers (%) by group experi-
encing each type of event should be shown. See
Table 2 as an example from the SAVOR-TIMI 53 trial
(Saxagliptin Assessment of Vascular Outcomes Recor-
ded in Patients with Diabetes Mellitus–Thrombolysis
In Myocardial Infarction 53) (2).
For any composite event (e.g., death, myocardial
infarction, and stroke), the number of patients expe-
riencing any of them (i.e., the composite) plus thenumbers in each component should all be
shown. Because some patients can have more
than 1 type of event (e.g., nonfatal myocar-
dial infarction followed by death), the
numbers in each component usually add up
to slightly more than the numbers with
composite events.
The focus is often on time to ﬁrst event, so
any subsequent (repeat) events (e.g., a sec-
ond or third myocardial infarction) do not get
included in the main analyses. This is not a
problem when the frequency of repeat events
is low. But for certain chronic disease out-
comes, such as hospitalization for heart fail-
ure, repeat events are more common. For instance, in
the CORONA (Controlled Rosuvastatin Multinational
Trial in Heart Failure) trial (3) of rosuvastatin versus
placebo in chronic heart failure, there were a total of
2,408 heart failure hospitalizations in 1,291 of 5,011
randomized patients. Conventional analyses of time
to ﬁrst hospitalization was inconclusive, but analyses
using all hospitalizations (including repeats) gave
strong evidence of a treatment beneﬁt in that sec-
ondary outcome (4).
In trials of chronic diseases (e.g., chronic heart
failure), in which the incidence rates over time are
fairly steady, it may be useful to replace % by the
incidence rate per 100 patient-years, for example, of
follow-up in each group: to calculate the incidence
rate one divides the number of patients with the
relevant event by the total follow-up time in years of
all patients (excluding any follow-up after an event
occurs). Such a table will usually add in estimates of
treatment effect, CIs, and p values, as dealt with in
the next 3 sections, and already shown in Table 2.
Another important table concerns adverse events by
treatment group.
KAPLAN-MEIER PLOT. The most common type of
Figure in major trial reports is a Kaplan-Meier plot of
time-to-event outcomes. Figure 1 shows this for the
primary outcome (death, myocardial infarction, or
stroke) of PLATO (Study of Platelet Inhibition and
Patient Outcomes) (5). The ﬁgure clearly displays
the steadily accumulating difference in incidence
rates between ticagrelor and clopidogrel. There are
several features that make for a good quality
Kaplan-Meier plot (6). The numbers at risk in each
group should be shown at regular time intervals of
follow-up. In this case, we see that nearly all patients
had 6months of follow-up, but only around one-half of
patients were followed for 1 year. In connection with
this, we recommend that the time axis should not
be extended too far, perhaps not beyond the time
when <10% of patients are still under follow-up.
TABLE 1 Characteristics of the Patients at Baseline in the PARADIGM-HF Trial
LCZ696
(N ¼ 4187)
Enalapril
(N ¼ 4212)
Age, yrs 63.8  11.5 63.8  11.3
Female 879 (21.0) 953 (22.6)
Race or ethnic group
White 2,763 (66.0) 2,781 (66.0)
Black 213 (5.1) 215 (5.1)
Asian 759 (18.1) 750 (17.8)
Other 452 (10.8) 466 (11.1)
Region
North America 310 (7.4) 292 (6.9)
Latin America 713 (17.0) 720 (17.1)
Western Europe and other 1,026 (24.5) 1,025 (24.3)
Central Europe 1,393 (33.3) 1,433 (34.0)
Asia-Paciﬁc 745 (17.8) 742 (17.6)
Systolic blood pressure, mm Hg 122  15 121  15
Heart rate, beats/min 72  12 73  12
Body mass index 28.1  5.5 28.2  5.5
Serum creatinine, mg/dl 1.13  0.3 1.12  0.3
Clinical features of heart failure
Ischemic cardiomyopathy 2,506 (59.9) 2,530 (60.1)
Left ventricular ejection fraction, % 29.6  6.1 29.4  6.3
Median B-type natriuretic peptide, pg/ml 255 (155–474) 251 (153–465)
Median N-terminal pro–B-type natriuretic
peptide, pg/ml
1,631 (885–3,154) 1,594 (886–3,305)
NYHA functional class
I 180 (4.3) 209 (5.0)
II 2,998 (71.6) 2,921 (69.3)
III 969 (23.1) 1,049 (24.9)
IV 33 (0.8) 27 (0.6)
Missing data 7 (0.2) 6 (0.1)
Medical history
Hypertension 2,969 (70.9) 2,971 (70.5)
Diabetes 1,451 (34.7) 1,456 (34.6)
Atrial ﬁbrillation 1,517 (36.2) 1,574 (37.4)
Hospitalization for heart failure 2,607 (62.3) 2,667 (63.3)
Myocardial infarction 1,818 (43.4) 1,816 (43.1)
Stroke 355 (8.5) 370 (8.8)
Pre-trial use of ACE inhibitor 3,266 (78.0) 3,266 (77.5)
Pre-trial use of ARB 929 (22.2) 963 (22.9)
Treatments at randomization
Diuretic agent 3,363 (80.3) 3,375 (80.1)
Digitalis 1,223 (29.2) 1,316 (31.2)
Beta-blocker 3,899 (93.1) 3,912 (92.9)
Mineralocorticoid antagonist 2,271 (54.2) 2,400 (57.0)
Implantable cardioverter-deﬁbrillator 623 (14.9) 620 (14.7)
Cardiac resynchronization therapy 292 (7.0) 282 (6.7)
Values are mean  SD, n (%), or median (interquartile range). Table summarizing the characteristics at the
baseline visit for patients in the PARADIGM-HF trial by treatment allocation. Adapted with permission from
McMurray et al. (1).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; NYHA ¼ New York Heart Asso-
ciation; PARADIGM-HF ¼ Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor with Angiotensin-
Converting–Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure.
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convey the extent of statistical uncertainty in the
estimates over time by plotting standard error (SE) bars
at regular time points. In this case, the SEs wouldbe much tighter at 6 months compared with 1 year,
reﬂecting the substantial proportion of patients not
followed out to 1 year.
Sometimes, Kaplan-Meier plots are inverted,
thereby showing the declining percentage of patients
over time that are event free. This can be particularly
misleading if there is a break in the vertical axis
(which readers may not spot). In general, we feel it is
more informative to have the curves going up (not
down), thereby focusing on cumulative incidence,
with a sensible range (up to 12% in this case) rather
than a full vertical axis up to 100%, so that relevant
details, especially regarding treatment differences,
can be clearly seen. The choice of vertical scale is an
important ingredient in interpreting these plots; not
so wide (0% to 100%) as to cramp the visual effect,
but not so tight as to exaggerate any small differences
that may occur.
REPEATED MEASURES OVER TIME. For quantitative
or symptom-related outcomes, repeated measures
over time are usually obtained at planned visits.
Consequent treatment comparisons of means (or %
with symptoms) are usually best presented in a
ﬁgure. See Figure 2 for mean systolic blood pressure
in the PARADIGM-HF trial (1), both in the build-up to
randomization and over the subsequent 3 years. Each
mean by treatment group should have SE bars around
it. In this case, the large numbers of patients make the
tiny SEs hard to see. With such precise estimation it is
obvious without formal testing that mean systolic
blood pressure is consistently around 2.5 mm Hg
lower on LCZ696 compared with enalapril, but this
secondary ﬁnding was peripheral to the trial’s main
aims concerning clinical events.
TRIAL PROFILE. As part of the CONSORT guidelines
for clinical trial reports (7), it is recommended
that every trial publication should have a trial proﬁle
that shows the ﬂow of patients through the trial
from the pre-randomization build-up to the post-
randomization follow-up. Figure 3 is an example from
the HEAT PPCI trial (How Effective Are Antith-
rombotic Therapies in Primary PCI) (8). It nicely
shows the high proportion of eligible patients who
were randomized, the small number not getting their
randomized treatment (but still included in intention
to treat analysis), the controversial delayed consent,
and the consequent small numbers removed from
analysis or lost to follow-up. The use of delayed
consent meant 17 patients died before consent could
be obtained, and for a further 17 surviving patients,
no consent was obtained. Figure 3 shows how 2,499
patients were identiﬁed, 1,829 were randomized,
and 1,812 were included in the analysis, with all
TABLE 2 Pre-Speciﬁed Clinical Endpoints in the SAVOR-TIMI 53 Trial
Saxagliptin
(n ¼ 8,280)
Placebo
(n ¼ 8,212)
Hazard Ratio
(95% CI) p Value
Cardiovascular death, myocardial
infarction, or stroke: primary
efﬁcacy endpoint
613 (7.3) 609 (7.2) 1.00 (0.89–1.12) 0.99
Cardiovascular death, myocardial
infarction, stroke, hospitalization
for unstable angina, heart failure,
or coronary revascularization:
secondary efﬁcacy endpoint
1,059 (12.8) 1,034 (12.4) 1.02 (0.94–1.11) 0.66
Death from any cause 420 (4.9) 378 (4.2) 1.11 (0.96–1.27) 0.15
Death from cardiovascular causes 269 (3.2) 260 (2.9) 1.03 (0.87–1.22) 0.72
Myocardial infarction 265 (3.2) 278 (3.4) 0.95 (0.80–1.12) 0.52
Ischemic stroke 157 (1.9) 141 (1.7) 1.11 (0.88–1.39) 0.38
Hospitalization for unstable angina 97 (1.2) 81 (1.0) 1.19 (0.89–1.60) 0.24
Hospitalization for heart failure 289 (3.5) 228 (2.8) 1.27 (1.07–1.51) 0.007
Hospitalization for coronary
revascularization
423 (5.2) 459 (5.6) 0.91 (0.80–1.04) 0.18
Doubling of creatinine level,
initiation of dialysis, renal
transplantation, or creatinine
>6.0 mg/dl (530 mmol/l)
194 (2.2) 178 (2.0) 1.08 (0.88–1.32) 0.46
Hospitalization for hypoglycemia 53 (0.6) 43 (0.5) 1.22 (0.82–1.83) 0.33
Values are n (%), unless otherwise indicated. 2-year Kaplan-Meier estimates and hazard ratios (95% conﬁdence
intervals [CIs]) for pre-speciﬁed clinical endpoints in the SAVOR-TIMI 53 trial. Percentages are 2-year Kaplan-
Meier estimates. Adapted from Scirica et al. (2).
SAVOR-TIMI 53 ¼ Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–
Thrombolysis In Myocardial Infarction 53.
FIGURE 1 Kaplan-Meier Estimates of the Cumulative Incidence Over Time of the First
Adjudicated Occurrence of the Primary Efﬁcacy Endpoint in the PLATO Trial
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Hazard ratio, 0.84 (95% CI, 0.77—0.92)
p < 0.001
No. at Risk
Ticagrelor
Clopidogrel
Ticagrelor
Clopidogrel
9333
9291
8628
8521
8460
8362
8219
8124
6743
6650
5161
5096
4147
4047
Cumulative incidence of the primary endpoint—a composite of death from vascular causes,
myocardial infarction, or stroke—was signiﬁcantly lower in the ticagrelor group than in
the clopidogrel group (9.8% vs. 11.7% at 12 months; hazard ratio: 0.84; 95% conﬁdence
interval [CI]: 0.77 to 0.92; p < 0.001). PLATO ¼ The Study of Platelet Inhibition and
Patient Outcomes. Reprinted with permission from Wallentin et al. (5).
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numbers. Note that with a more conventional patient
consent prior to randomization, the trial proﬁle
would become somewhat simpliﬁed.
The next most common ﬁgure is the forest plot for
subgroup analyses, but more on that in next week’s
paper.
ESTIMATES OF TREATMENT EFFECTS
AND THEIR CIs
Now we get down to the serious business of esti-
mating the magnitude of the difference between
treatments on patient outcomes. First, we wish to
obtain a point estimate, that is, the actual difference
observed. Then we need to express the degree of
uncertainty present in the data, that is, the bigger the
trial, the more precise the point estimate will be. Such
uncertainty is usually expressed as a 95% CI.
Exactly what type of estimate is required depends
on the nature of the patient outcome of interest.
There are 3 main types of outcome data:
1. A binary (yes/no) response, for example, success or
failure, dead or alive, or in the trial we pursue,
below the composite of death, myocardial infarc-
tion, ischemia-driven revascularization, or stent
thrombosis (i.e., did any of these occur within 48 h
of randomization in percutaneous coronary inter-
vention [PCI] patients, yes or no)?
2. A time to event outcome, for example, time to
death, time to symptom relief, or in the trial we
pursue, below the time to ﬁrst hospitalization for
heart failure or cardiovascular death, whichever
(if either) happens ﬁrst.
3. A quantitative outcome, for example, change in
systolic blood pressure from randomization to 6
months later.
What follows are the standard estimation methods
for these 3 types of data. In the process, we also
explain what a CI actually means.
ESTIMATES BASED ON PERCENTAGES. In acute
disease, the comparative efﬁcacy of 2 treatments is
often assessed by “success or failure” in terms of
“absence or presence” of a serious clinical event. For
instance, in the CHAMPION-PHOENIX trial (Cangrelor
versus Standard Therapy to Achieve Optimal Man-
agement of Platelet Inhibition PHOENIX) (9), the
primary outcome was the composite of death,
myocardial infarction, ischemia-driven revasculari-
zation, or stent thrombosis within 48 h of randomi-
zation. Patients undergoing PCI were randomized to
cangrelor or clopidogrel (n ¼ 5,470 and n ¼ 5,469,
respectively) and the numbers (%) experiencing
FIGURE 2 Systolic Blood Pressure During Run-In And After Randomization in the PARADIGM-HF Trial
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Mean difference (95% CI)
–2.70 (–3.07, –2.34) mm Hg, p < 0.001
Mean systolic blood pressure (SBP) by visit and treatment group, and overall mean difference (95% conﬁdence interval [CI]) in the
PARADIGM-HF trial. PARADIGM-HF ¼ Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor with Angiotensin-Converting–
Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure. Reprinted, with permission, from McMurray et al. (1).
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2540the primary composite outcome were 257 (4.7%) and
322 (5.9%), respectively. The various estimates of
comparative treatment efﬁcacy based on these 2
percentages are displayed in Table 3, with each esti-
mate accompanied by its 95% CI.
Relative risk is the ratio of 2 percentages, here 0.798,
and can be converted to the relative risk reduction,
which on a percentage scale is 20.2%. A common
alternative to relative risk is relative odds, here 0.788.
This is less readily understandable, because except for
those who gamble on horses, the concept of odds is
harder to grasp. However, as explained later, relative
odds are linked to logistic regression, which permits
adjustment for baseline variables. Relative risk and
relative odds are sometimes called risk ratio and odds
ratio instead. If event rates are small then the 2 give
quite similar estimates, with the odds ratio always
slightly further away from 1.
The absolute difference in percentages, here 1.19%,
is another important statistic. It is sometimes called
the absolute risk reduction. In trial reports, it is useful
to present both the absolute and relative risk reduc-
tion. The former expresses the estimated absolute
beneﬁt across all randomized patients in avoiding
the primary endpoint by giving cangrelor instead
of clopidogrel. The latter expresses in relative termswhat estimated percentages of primary events on
clopidogrel would have been prevented by using
cangrelor instead.
The difference in percentages can be converted
into the number needed to treat (NNT), here 84.0. This
means that to prevent 1 primary event by using can-
grelor instead of clopidogrel we need to treat an
estimated 84 patients. For NNT, it is important to
note the relevant timeframe: here it is 48 h post-
randomization.
EXPRESSING UNCERTAINTY USING CIs. All esti-
mates based on percentages, such as in Table 3 (and,
indeed, other types of estimates to follow in the next 2
sections) are not to be trusted at face value. Any es-
timate has a built-in imprecision because of the ﬁnite
sample of patients studied, and indeed the smaller the
study, the less precise the estimate will be. The extent
of such statistical uncertainty is best captured by use
of a 95% CI around any estimate (10,11).
For instance, the observed relative risk reduction
of 20.2% has a 95% CI from 6.4% to 32.0%. What does
this mean? In simple terms, we are 95% sure that the
true reduction with cangrelor versus clopidogrel lies
between 6.4% and 32.0%. However, the frequentist
principles of statistical inference, which underpin all
use of conﬁdence intervals and p values, give a more
FIGURE 3 Trial Proﬁle of the HEAT-PPCI Trial
2490 PPCI activations at the host institution during recruitment period
  12 cases when pathway activated in error
101 other (non-PPCI) emergencies used pathway
  36 cases did not arrive at PPCI centre 
401 judged as incorrect activations (not STEMI)
  23 suspected STEMI cases did not have angiography
1917 patients scheduled for emergency angiography
29 (2%) previous randomization in the trial
59 (3%) met other exclusion criteria
    42 had factors precluding DAPT (eg, ventilation)
      9 cases physician refused to administer DAPT
      7 had contraindication to DAPT or trial drugs
      1 had active bleeding
1829 eligible for recruitment
1829 randomized in the trial
914 were assigned to receive heparin
900 (98%) received treatment as allocated
14 did not receive any trial medication
915 were assigned to receive bivalirudin
   907 (99%) received treatment as allocated
      1 received heparin only
      7 did not receive any trial medication
3 received LMWH preprocedure
7 died before consent
  4 received LMWH preprocedure
10 died before consent
7 (1%) surviving patients have no
   consent available
   6 unable to get consent
   1 withdrew consent
   0 refused consent
10 (1%) surviving patients have no
   consent available
   7 unable to get consent
   0 withdrew consent
   3 refused consent
907 follow up complete for index admission 905 follow up complete for index admission
2 (<1%) lost to follow up at 28 days 0 lost to follow up at 28 days
907 included in the analysis 905 included in the analysis
Trial proﬁle for HEAT-PPCI summarizing the ﬂow of patients through the trial from the pre-randomization recruitment period to the post-
randomization follow-up and analysis. Reprinted with permission from Shahzad et al. (8). DAPT ¼ dual antiplatelet therapy; HEAT-PPCI ¼ How
Effective Are Antithrombotic Therapies in Primary PCI; LMWH ¼ low-molecular-weight heparin; PPCI ¼ primary percutaneous coronary
intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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TABLE 3 Estimates Based on the Comparison of 2 Percentages, Illustrated by the
Primary Outcome* of the CHAMPION-PHOENIX Trial
Cangrelor Clopidogrel
Randomized patients, n 5,470 5,469
Patients with primary outcome, n (%) 257 (4.698)† 322 (5.888)†
Estimate Formula Result
Relative risk (95% CI) 4:698
5:888
¼ 0:798 ð0:680 to 0:936Þ
Relative risk reduction (95% CI) ð1  0:798Þ  100 ¼ 20:2% ð6:4% to 32:0%Þ
Relative odds (95% CI)
4:698=ð100  4:698Þ
5:888=ð100  5:888Þ ¼ 0:788 ð0:666 to 0:932Þ
Difference in percentages (95% CI) 4:698  5:888 ¼ 1:19% ð0:35% to  2:03%Þ
Number needed to treat (95% CI)
100
1:19
¼ 84:0 ð49:3 to 285:7Þ
Number and percentage of patients with a primary outcome (death, myocardial infarction, ischemia driven
revascularization, or stent thrombosis within 48 h of randomization) in the CHAMPION-PHOENIX trial along with
various estimates of treatment effect. *Primary composite outcome is death, myocardial infarction, ischemia-
driven revascularization, or stent thrombosis within 48 h of randomization. †In the middle of all numerical
calculations, any values (e.g., percentages) should be precise (e.g., to $3 decimal places). Only at the ﬁnal step
should values be rounded for convenience of expression.
CHAMPION-PHOENIX ¼ Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet In-
hibition PHOENIX trial; CI ¼ conﬁdence interval.
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whole clinical trial many, many times using an iden-
tical protocol we would get a slightly different conﬁ-
dence interval each time. Of those CIs, 95% would
contain the true underlying relative risk reduction.
But, whenever we calculate a 95% CI, there is a 2.5%
chance that the true effect lies below and a 2.5%
chance that the true effect lies above the interval.
What matters here is that the whole 95% CI
indicates a clear relative risk reduction. This is rein-
forced by 95% CI for the difference that is
from 0.35% to 2.03% (Table 3). These relatively
tight CIs, each wholly in a direction substantially
favoring cangrelor, provides strong evidence that
cangrelor reduces the risk of the primary endpoint
compared with clopidogrel. Later, we achieve the
same message by use of a p value. Note that Table 3
also gives a 95% CI for the NNT. Some trials report
the NNT but not its 95% CI, a practice to be avoided
because readers can be led astray by thinking that the
NNT is precisely known.
An important obvious principle is that larger studies
(more patients and hence more events) produce more
precise estimation and tighter CIs. Speciﬁcally, to
halve the width of a CI, one needs 4 asmany patients.
This logic feeds into statistical power calculations
when designing a clinical trial (see future paper in this
series).
Another issue is: why choose 95% conﬁdence, and
why not 90% or 99%? Well, there is no universal
wisdom that says 95% is the right thing to do. It is just a
convenient fashion that, for consistency’s sake,
virtually all papers follow. It also has a link to p< 0.05,as discussed in the following text. It is worth noting
that “conﬁdence” is not evenly distributed over a 95%
CI. For instance, there is around a 70% chance that the
true treatment effect lies in the inner one-half of the
95% CI. Also, 1.5  (95% CI width) ¼ 99.9% CI.
ESTIMATES FOR TIME-TO-EVENT OUTCOMES. Many
major clinical trials have a primary outcome, which is
time to an event. In the PLATO trial (5) (Figure 1), the
Kaplan-Meier plot is for time to the primary composite
outcome of death, myocardial infarction, and stroke.
The curves diverge in favor of ticagrelor, but do not in
themselves provide a simple estimate summarizing
the treatment difference. One can read off the
Kaplan-Meier estimate at the end of plotted time,
1 year in this instance, and they are 1-year cumulative
rates of 9.8% and 11.7% for ticagrelor and clopidogrel,
respectively. If everyone had been followed for 1 year
this would have merit (and a 95% CI for the treatment
difference 1.9% could be calculated), but given that
only around one-half of the patients have been
followed for a year, this is far from ideal.
Instead, the most common approach is to use a Cox
proportional hazards model to obtain a hazard ratio
and its 95% CI, which in this case is 0.84 (95% CI: 0.77
to 0.92). Technically, the instantaneous hazard rate at
any speciﬁc time point is the probability of the out-
come occurring exactly at that time for patients who
are still outcome-free. The hazard ratio can be thought
of as the hazard rate in one group (ticagrelor) divided
by the hazard rate in the other group (clopidogrel)
averaged over the whole follow-up period. Conceptu-
ally, it is similar to the relative risk (risk ratio), except
that follow-up time is taken into account (12).
In this example, the hazard ratio and its 95% CI are
all substantially <1 indicating strong evidence of
fewer primary outcomes on ticagrelor compared to
clopidogrel. For those who like a more straightforward
statistical life, we note that the numbers of patients
having the primary outcome are 864 and 1,014 in the
ticagrelor and clopidogrel groups, respectively. The
simple ratio 864/1,014 ¼ 0.852 is very similar to the
hazard ratio, as will usually be the case for trials with
equal randomization and relatively low event rates.
The hazard ratio is best suited to data where
the Kaplan-Meier plot shows a steady divergence
between treatment groups. But, in some trials, espe-
cially with surgical intervention, one might anticipate
an early excess risk followed by a subsequent gain
in efﬁcacy as time goes by. For instance, the
FREEDOM trial (Future Revascularization Evaluation
in Patients with Diabetes Mellitus: Optimal Manage-
ment of Multivessel Disease) (13) of coronary artery
bypass grafting (CABG) versus PCI has a primary
FIGURE 4 Kaplan-Meier Estimates of the Cumulative Incidence Over Time of the
Primary Efﬁcacy Endpoint in the FREEDOM Trial
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(25). CABG ¼ coronary artery bypass graft; PCI ¼ percutaneous coronary intervention.
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2543composite endpoint of death, myocardial infarction,
or stroke (Figure 4). An early excess event rate for
CABG (mainly due to stroke) is followed by a lower
event rate after the ﬁrst 6 months. The Kaplan-Meier
curves cross at around 1 year. Here, a hazard ratio
would be a peculiar average of early bad news
followed by later good news for CABG, and so is
not particularly useful. The focus on the 5-year
composite event rate (18.7% on CABG, 26.6% on PCI)
is informative, but suffers from the fact that only
around one-third of patients have so far been
followed for 5 years. A more complete 5-year follow-
up is required to clarify this.
Another problem with hazard ratios is that they
focus on a “vertical interpretation” of the Kaplan-
Meier plot. But, in chronic diseases, a more “horizon-
tal interpretation” focusing on event-free time gained
may be more appropriate. The accelerated failure time
model (14) is unfortunately rarely used, but it can
nicely capture this concept. In a nutshell, it estimates a
time ratio whereby if a new treatment helps to delay
the occurrence of events, the time ratio will be >1. For
instance, a time ratio of 1.5 means that, on average, it
takes 50% longer for an event to occur in patients on
the new treatment compared with control subjects.
We illustrate the use of the accelerated failure
time model in a post hoc analysis of the EMPHASIS-HF
(Eplerenone in Mild Patients Hospitalization and
Survival Study in Heart Failure) trial (15) of epler-
enone versus placebo in patients with systolic heart
failure and mild symptoms. The primary composite
endpoint, heart failure hospitalization or cardiovas-
cular death, is plotted in Figure 5. Reading off hori-
zontally from this plot, the eplerenone and placebo
groups reach 10% incidence at 0.84 and 0.40 years,
respectively, a time ratio of 2.10. The 20% incidence
occurs at 2.02 and 1.09 years, respectively, a time ratio
of 1.86. The accelerated failure time model averages
these time ratios across all possible cut-offs on the
vertical scale of Figure 4. The end result is a time ratio
of 1.71 in favor of eplerenone, with 95% CI: 1.38 to 2.11.
An alternative simpler approach is to calculate
the incidence rate of the primary endpoint over all
follow-up: for eplerenone and placebo groups this is
10.60 and 15.47 per 100 patient-years, respectively.
This gives a rate ratio of 0.69, the inverse of which is
the time ratio 1.47. This crude approach works well,
provided incidence rates are fairly steady throughout
follow-up. But, in general, the Kaplan-Meier plot in
many diseases shows a much higher incidence rate in
early follow-up.
ESTIMATES FOR QUANTITATIVE OUTCOMES. In anal-
yzing a quantitative outcome, one usually comparesthemeans in 2 treatment groups. However, as the same
outcome is usually measured at baseline, it is more
efﬁcient to compare mean changes from baseline. Yet,
this still misses the fact that changes tend to depend on
the baseline value, based on the concept of regression
to the mean. That is, patients with high baseline value
tend to have a bigger fall in value than patients with
lower baseline values. This requires an analysis of
covariance (ANCOVA), in which one compares mean
changes adjusted for baseline value (16).
We illustrate these issues using results for the
primary endpoint, 6-month change in systolic blood
pressure (SBP) in the SYMPLICITY HTN-3 trial (Renal
Denervation in Patients With Uncontrolled Hyper-
tension) (17) comparing renal denervation with a
sham procedure in a 2:1 randomization (n ¼ 350 and
n ¼ 169 patients for renal denervation and sham,
respectively) (Table 4).
First, note the relatively poor showing of an
analysis of the 6-month SBP only, ignoring baseline:
this fails to account for the marked variation in
patients’ baseline blood pressure, and hence yields a
wider 95% CI. The comparison of the 2 analyses of
mean changes, with and without adjustment for
baseline, is more subtle. Results are fairly similar,
but it is statistically inevitable that ANCOVA
produces a slightly more precise estimate of the
TABLE 4 6-Month Results From the SYMPLICITY HTN-3 Trial
SBP at 6 months 4.20 (9.17 to þ0.77)
6-month change in SBP 4.07 (8.63 to þ0.49)
6-month change in SBP adjusted
for baseline SBP using ANCOVA
4.11 (8.44 to þ0.22)
Values are mean treatment difference (95% conﬁdence interval) in mm Hg. Three
different methods of analyzing 6-month systolic blood pressure (SBP) results from
the SYMPLICITY HTN-3 trial of renal denervation versus a sham procedure.
ANCOVA ¼ analysis of covariance; SYMPLICITY HTN-3 ¼ Renal Denervation in
Patients With Uncontrolled Hypertension.
FIGURE 5 Time to Primary Event in the EMPHASIS-HF Trial
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2544treatment effect, that is, its 95% CI is a bit tighter
(18). Even so, in this case, the 95% CI still includes
zero treatment difference, meaning that there is
insufﬁcient evidence that renal denervation lowers
SBP in this population.
What ANCOVA is doing is illustrated in Figure 6,
which plots individual 6-month change in SBP by
baseline SBP using different symbols for the 2
treatment groups. The 2 drawn parallel regression
lines show the anticipated regression to the mean,
that is, patients near to the minimum eligible base-
line SBP of 160 mm Hg have (in both treatment
groups) a tendency to have less blood pressure
reduction compared with those starting at higher
levels. The vertical distance between the 2 regression
lines is 4.11 mm Hg, the mean treatment effect
adjusted for baseline. Note that this kind of scatter
diagram is a useful reminder as to the huge indi-
vidual variation in SBP over time (with or without
treatment), which is why we need clinical trials of
several hundred patients to detect realistic treatment
effects.
One issue is whether to choose absolute change (as
here) or percentage change from baseline. Statisti-
cally, it depends on which gives the better model ﬁt
using ANCOVA.When a quantitative outcome is measured repeat-
edly over time at planned visits, there are various
options for statistical analysis, depending on what
estimate of treatment effect one wishes to focus on. It
could be: 1) the mean treatment difference averaged
over time, as in the PARADIGM-HF trial (1) SBP data in
Figure 2; 2) the differing rates of decline (slopes) in,
say, forced expiratory volume in a study of deterio-
rating respiratory function; or 3) a mean treatment
effect at a speciﬁc point of follow-up, for example,
glycated hemoglobin at 18 months in a trial evalu-
ating glycemic efﬁcacy of antidiabetic drugs. In
each case, the correlation structure in each within-
patient trajectory is used in a repeated measures
analysis, often with variation in the extent of patient
FIGURE 6 Analysis of Covariance for Change in SBP in the SYMPLICITY HTN-3 Trial
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2545follow-up, to provide the most valid estimate based
on the totality of patient data.
Sometimes, a quantitative outcome has a highly
skewed distribution so that a conventional analysis
of means becomes unstable because of its depen-
dence on a few extreme values. Options then are:
1) to use a suitable transformation (e.g., natural log-
arithm leading to comparison of geometric means);
2) to use nonparametric analyses, often focusing on a
comparison of medians; or 3) to focus on a particular
cut-off value(s) (e.g., the upper limit of normal in
liver function tests) with a consequent comparison of
percentages.
p VALUES AND THEIR INTERPRETATION
Wehave deliberately delayed explaining p values until
after covering descriptive statistics, estimation, and
CIs. This is an attempt to counter the obsessive ten-
dency for people to classify a clinical trial into
“positive” or “negative” depending on whether or
not the primary endpoint achieves p < 0.05. This
oversimpliﬁcation is an abuse of the p value, whichcan be a valuable statistical tool when interpreted
appropriately.
Alongside an estimate of treatment difference
and its 95% CI, the corresponding p value is the most
succinct direct route to expressing the extent to
which it looks plausibly like a real treatment effect,
or rather could readily have arisen by chance. At
the heart of any signiﬁcance test is the null hy-
pothesis that the 2 treatments are identical in their
effect on the outcome of interest. The p value is the
probability of obtaining a treatment difference at
least as great (in either direction) as that actually
observed if the null hypothesis were true. The
smaller the p value, the stronger the evidence
against the null hypothesis, that is, the more
convincing the evidence is that a genuine treatment
difference exists.
Let us consider some recent trials to elucidate the
range of their p values for the primary endpoint. In
doing so, our aim is to translate statistical evidence
into plain English (19). The PARADIGM-HF trial (1)
compared a new drug, LCZ696, with enalapril in
patients with chronic heart failure. For the primary
TABLE 5 A Useful Language for Interpreting p Values
p < 0.001 Overwhelming evidence
0.001 # p < 0.01 Strong evidence
0.01 # p < 0.05 Some evidence
0.05 # p < 0.10 Insufﬁcient evidence
p $ 0.10 No evidence
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2546endpoint, heart failure hospitalization or cardiovas-
cular death over a median 27 months of follow-up, the
hazard ratio was 0.80 with 95% CI: 0.73 to 0.87 and
p ¼ 0.0000004. Such a small p value means that if
LCZ696 were truly no better than enalapril, the
chances of getting this magnitude of treatment dif-
ference (or greater) is <1 in a million.
Such a small p value provides overwhelming evi-
dence of a treatment difference. Such proof beyond
reasonable doubt means one can conﬁdently assert
that LCZ696 is superior to enalapril with regard to the
incidence of the primary endpoint.
The CHAMPION-PHOENIX trial (9) of cangrelor
versus clopidogrel had an odds ratio of 0.788 with
95% CI: 0.666 to 0.932 for its primary endpoint
(Table 3). Here, p ¼ 0.005 means that there is a 1 in
200 chance of such a difference (or greater) arising by
chance; this is not as thoroughly convincing as the
PARADIGM-HF trial, but is still strong evidence of a
treatment beneﬁt (i.e., cangrelor appears to be supe-
rior to clopidogrel). Note that the trial report (9) gave
an adjusted odds ratio and so on; we discuss covariate
adjustment in next week’s paper.
IMPROVE-IT (Improved Reduction of Outcomes:
Vytorin Efﬁcacy International trial) (20) compared
ezetimibe with placebo in 18,144 post-ACS patients
receiving simvastatin 40 mg. The primary composite
endpoint over a mean 5.4 years was cardiovascular
death, myocardial infarction, stroke, unstable angina,
and coronary revascularization, with hazard ratio of
0.936 (95% CI: 0.888 to 0.988). Here, p ¼ 0.016 means
that there is a <1 in 50 chance of such a difference
(or greater) arising by chance. This provides some
evidence of a treatment beneﬁt: it reaches the oft-
used guideline of p < 0.05, that is, statistically sig-
niﬁcant at the 5% level. There is a 6.4% relative risk
reduction and an absolute treatment difference of
2.0%, both with wide CIs. This suggests a modest
treatment beneﬁt that is imprecisely estimated.
In the SYMPLICITY HTN-3 trial (17) (Figure 5), the
mean difference between renal denervation and sham
procedure in 6-month change in SBP adjusted for
baselinewas4.11mmHg, with 95%CI:8.44 toþ0.22
mm Hg, and p ¼ 0.064. Under the null hypothesis that
renal denervation is ineffective, this observed magni-
tude of treatment difference has more than a 1 in
20 chance of occurring. Because p > 0.05 (i.e., 5% sig-
niﬁcance is not achieved), it is customary to declare
that there is insufﬁcient evidence that renal denerva-
tion reduces SBP. This should not be interpreted
dogmatically that renal denervation has no effect
(i.e., the null hypothesis is not necessarily true).
Rather, we should declare there is insufﬁcient evi-
dence that renal denervation lowers SBP comparedwith a sham procedure. It may be that renal denerva-
tion has a modest effect OR it may have no effect: the
data are inconclusive.
Now, to a more clearly neutral ﬁnding. The
ASTRONAUT trial (Aliskiren Trial on Acute Heart Fail-
ure Outcomes) (21) randomized 1,639 patients with
hospitalized heart failure to aliskiren or placebo with a
median 11.3 months of follow-up. The primary
endpoint, rehospitalization for heart failure or car-
diovascular death, had a hazard ratio of 0.92 (95% CI:
0.76 to 1.12), with p ¼ 0.41. With such a clearly
nonsigniﬁcant p value, there is no evidence that alis-
kiren has an effect on the primary endpoint. However,
we still cannot assert deﬁnitively that aliskiren has no
effect: the hazard ratio is in the direction of slightly
fewer primary events on aliskiren and the wide CI ex-
tends a substantial distance from neutrality (hazard
ratio: 1) in both directions.
Thus, we may think of p values not as a “black
and white” signiﬁcant/nonsigniﬁcant dichotomy, but
more in terms of “shades of gray” (22). This analogy to
a recent movie is not to make statistics sexy, nor is it
to suggest that statisticians are sadists, but it is more
in the spirit of the expression’s original meaning. The
smaller the value of p, the stronger the evidence to
contradict the null hypothesis of no true treatment
difference. We can think of p < 0.000001 as “pure
white” and p ¼ 0.99 as “pure black,” with a trend of
increasingly darkening grayness in-between those
extremes. Table 5 summarizes a useful vocabulary
that might be applied to interpreting p values.
A brief history of the p value and its variety of
interpretations is provided in the Online Appendix.
“A p VALUE IS NO SUBSTITUTE FOR A BRAIN.” This
quote from Stone and Pocock (23) is to remind us
all that interpretation of a seemingly “positive” trial
rests on more than just a signiﬁcant p value:
1. It is good practice to give the actual p value (i.e.,
p ¼ 0.042 rather than p < 0.05 or crudely
“signiﬁcant,” or p ¼ 0.061 rather than “not
signiﬁcant”).
2. It is useful to recognize the link between the p value
and the 95% CI for the treatment difference. If the
latter includes no difference, that is, 0 on an
absolute scale (e.g., % or mean difference) or 1 on a
TABLE 6 The Simplest Statistical Test*
z p Value
1.64 0.1
1.96 0.05
2.58 0.01
2.81 0.005
3.29 0.001
3.48 0.0005
3.89 0.0001
ab
ﬃﬃﬃﬃﬃﬃ
aþbp
is approximately a standardized normal deviate, z; a and b are the numbers
having an outcome event in the 2 treatment groups. This table displays some
useful z values. The larger the z, the smaller the p value. *Only suitable for trials
with 1:1 randomization. Most reliable when proportions having events are small.
Should be conﬁrmed by the more complex test (e.g., log-rank).
TABLE 7 4 Examples Using z
Trial Name (Ref. #)
Patients With an Event (n)
z
ab
ﬃﬃﬃﬃﬃﬃﬃ
aþbp p Value InterpretationControl (a)
New
Treatment (b)
PARADIGM-HF (1) 1,117 914 4.50 <0.00001 Overwhelming
evidence
CHAMPION-PHOENIX (9) 322 257 2.70 0.007 Strong evidence
IMPROVE-IT (20) 2,742 2,572 2.33 0.02 Some evidence
ASTRONAUT (21) 214 201 0.64 0.52 No evidence
ASTRONAUT ¼ Aliskiren Trial on Acute Heart Failure Outcomes; IMPROVE-IT ¼ Examining Outcomes in Subjects
With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103); other abbreviations as
in Tables 1 and 3.
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2547ratio scale (e.g., relative risk or hazard ratio), then
we know p > 0.05. Conversely, if the 95% CI is
wholly 1 side of the null value, then we know
p < 0.05.
3. It is best if we always use 2-sided p values. That is,
under the null hypothesis, p is the probability
of getting a difference in either direction as big
as (or bigger) than that observed. Occasionally,
people will argue that they are only interested in
1 direction of treatment effect (new treatment
superior) and, hence, should be allowed to halve
the p value in a 1-sided test. For instance, the
CoreValve trial (24) claimed 1-sided p ¼ 0.04 for
lower mortality on transcatheter aortic valve
replacement versus surgery, rather than the con-
ventional 2-sided p ¼ 0.08. This practice is to be
avoided, because it produces an inconsistency
across trial reports and makes it a bit too easy to
achieve p < 0.05.
4. A small p value clariﬁes that an observed treatment
difference appears greater than what could be
attributed to chance, but this does not automati-
cally mean that a real treatment effect is occurring.
There may be biases in the study design and conduct
(e.g., randomization could be absent or ﬂawed,
lack of appropriate blinding, or incomplete follow-
up), which contribute wholly or in part to the
apparent treatment difference. These issues con-
tribute to why regulators often require 2 trials be
conducted to demonstrate a reassuring consis-
tency of ﬁndings in 2 different settings.
5. There is an important distinction between statis-
tical signiﬁcance and clinical relevance of a treat-
ment effect. Here, the magnitude of treatment
difference and its CI are a guide as to whether the
beneﬁt of a new treatment is sufﬁciently great to
merit its use in clinical practice.
6. For a small trial to reach a statistically signiﬁcant
treatment effect, the magnitude of treatmentdifference needs to be very large. For instance, a
trial of acetylcysteine versus placebo to prevent
contrast-induced nephropathy (25) reported 1 of 41
and 9 of 42 acute reductions in renal failure
(p ¼ 0.01). This ﬁnding has a risk ratio of 0.11 with a
very wide 95% CI: 0.015 to 0.859. The observed
result is “too good to be true.” A comparable small
trial with a nonsigniﬁcant ﬁnding would doubtless
not have been published in a major journal. Thus,
publication bias, that is, the tendency for
published trials to exaggerate treatment effects, is
accentuated when trials are small.
7. In this paper, we concentrate on interpreting p
values (and CIs) for trials whose purpose is to
determine if one treatment is superior to another.
For noninferiority trials, with the goal of seeing if a
new treatment is as good as the control, interpre-
tation is somewhat different, as explained in the
last paper in this series.
THE SIMPLEST STATISTICAL TEST. This paper does
not provide the statistical calculations or programs
required to obtain p values. Sufﬁce it to say that for
the 3 types of outcome data, binary, time-to-event,
and quantitative, the most commonly used tests are
chi-square, log-rank, and 2-sample Student t test
or ANCOVA, respectively. But, for trials with 1:1
randomization and a binary or time-to-event out-
come, there does exist a quick alternative (26) that
can be used by the inquisitive reader who is “dying
to know” if a result is statistically signiﬁcant. The
test is so simple that most statisticians do not know
about it!
All you need to use is the number of patients
in each treatment group who have the primary
endpoint. Then, the difference divided by the
square root of the sum is approximately a stan-
dardized normal deviate, which can readily be
converted into a p value (Table 6). See Table 7 for
how it works for 4 of the trials we have already
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What to include in result tables and figures1
Quantify associations2 Express uncertainty3 Assess evidence4
Table of Baseline Data
First table for any
clinical trial report
• Total nos. of patients
per group
• Key demographic variables
• Related medical history
• Other endpoint-
related variables
Confidence interval 
Estimates will always have built-in imprecision 
because of the finite sample of patients studied
• Always acknowledge a degree of uncertainty
(95% confidence interval, “95% CI”)
• Larger studies provide more reliable estimates 
with tighter confidence intervals (i.e., 99% CI)
Estimate treatment effect (numerous methods):
• Relative risk/relative odds for binary outcomes
• Relative risk reduction
• Absolute difference in percentage
• Number Needed to Treat (NNT)
• Hazard ratio for time-to-event outcomes
• Mean difference using ANCOVA
for quantitative outcomes
P values and interpretation
Determine whether there is real treatment effect 
The smaller the value of P the stronger the 
evidence to contradict the null hypothesis of 
no true treatment difference
• Report actual p value, i.e., p = 0.042
• Note if p value meets significance level (p < 0.05)
• Use two-sided p values
THE FOUR MAIN STEPS IN DATA ANALYSIS AND REPORTING FOR CLINICAL TRIALS
Table of Main
Outcome Events
• Main outcome by group
• Nos. (%) experiencing 
endpoint by group
• For composite endpoints 
report nos. (%) experiencing 
each component event
• Analysis of first and 
subsequent events
Kaplan-Meier Plot
of cumulative incidence
over time, by group
Common figure in
major trial reports
• Focus on cumulative 
incidence
• Sensible vertical axis range
• Report number at risk
over follow-up time
Repeated Measures
Over Time
Figure to show change in 
mean over time by group
• Standard error bars
to express uncertainty
Trial Profile
Flow of patients
through trial
• Nos. of eligible
patients identified
• Nos. randomized into trial
• Nos. lost to follow-up
• Nos. included in analysis
Pocock, S.J. et al. J Am Coll Cardiol. 2015; 66(22):2536–49.
ANCOVA ¼ analysis of covariance; CI ¼ conﬁdence interval; NNT ¼ number needed to treat.
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2548discussed. In each case, this simple test agrees well
with the more complex calculations used in the trial
publication.
CONCLUSIONS
We have covered the essentials of statistical analysis
and reporting in this paper, and the key aspects are
summarized in the Central Illustration. Next week
we tackle a variety of more complex statistical chal-
lenges that are often faced in the reporting of clinical
trials. These include multiplicity of data, covariateadjustment, subgroup analysis, assessing individual
beneﬁts and risk, analysis by intention to treat and
alternatives, the interpretation of surprises (both
good and bad), and enhancing the overall quality of
clinical trial reports.
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